The TRIple Elimination Model Of Mother-to-child Transmission Program (TRI-MOM) (TRI-MOM)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05951751 |
Recruitment Status :
Not yet recruiting
First Posted : July 19, 2023
Last Update Posted : July 19, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The TRI-MOM program aims to implement and evaluate a simplified (based on inexpensive rapid diagnostic tests), integrated (in governmental health facilities) and coordinated (between health care workers) strategy for the triple elimination of HIV, syphilis and HBV mother-to-child transmission (MTCT) in nine maternal and child health services, 5 in Burkina Faso and 4 in The Gambia.
The TRI-MOM program has two components:
- an "intervention" component consisting of a pilot study to reinforce the antenatal screening and prevention of MTCT (PMTCT) capacities for the 3 targeted infections through the implementation of a simplified, integrated and coordinated strategy of triple elimination of MTCT.
- an "evaluation" component which will assess the impact of the TRI-MOM strategy on PMTCT services, reduction of HBV MTCT and women empowerment.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hiv Syphilis HBV | Other: TRI-MOM intervention | Not Applicable |
The TRI-MOM (TRIple elimination Model Of Mother-to-child transmission of HIV/Syphilis and HBV in Burkina Faso and The Gambia) program aims to implement and evaluate a simplified (based on inexpensive rapid diagnostic tests), integrated (in governmental health facilities) and coordinated (between health care workers) strategy for the triple elimination of HIV, syphilis and HBV MTCT in nine maternal and child health services, 5 in Burkina Faso and 4 in The Gambia. In The Gambia, the program will be conducted in collaboration with the national HIV, sexually transmitted infections (STI) and hepatitis programmes.
The TRI-MOM program has two components:
- an "intervention" component consisting of a pilot study to reinforce the antenatal screening and PMTCT capacities for the 3 targeted infections through the implementation of a simplified, integrated and coordinated strategy of triple elimination of MTCT. This pilot study will be conducted in 9 selected maternities.
- an "evaluation" component which will assess the impact of the TRI-MOM strategy on PMTCT services, reduction of HBV MTCT and women empowerment.
Intervention component :
The TRI-MOM strategy includes 4 main activities:
- Training of healthcare professionals in charge of maternal health (nurses, midwives and doctors in charge of maternal health services)
- Triple screening of HIV, Syphilis and HBV by rapid diagnostic tests
- Assessment and treatment of women positive for any of the 3 targeted infections
- Raising awareness on MTCT among pregnant women visiting antenatal services and empowering women infected with at least one of the three infections
Evaluation component :
The TRI-MOM program will include three studies :
- A quantitative and qualitative cross-sectional study before and after the implementation of the strategy.
- A cohort study of pregnant women positive for any of the three infections.
- Cost and cost-effectiveness analysis.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 2800 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Health Services Research |
Official Title: | Integrated Antenatal Screening for HIV, Syphilis, and Hepatitis B Virus (HBV) in Pregnant Women in Burkina Faso and The Gambia |
Estimated Study Start Date : | September 2023 |
Estimated Primary Completion Date : | May 2025 |
Estimated Study Completion Date : | May 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: TRI-MOM
Women attending their first postnatal visit in one of the selected maternities (no maternal age limit) will be eligible to participate in the study
|
Other: TRI-MOM intervention
The TRI-MOM strategy includes 4 main activities:
|
- Coverage of the strategy in the study maternities before its implementation [ Time Frame: Assessed cross-sectionally using a questionnaire administered to women at baseline (before the implementation of the TRI-MOM strategy) ]Proportion of women screened for HIV, Syphilis and HBV during pregnancy
- Coverage of the strategy in the study maternities after its implementation [ Time Frame: Assessed cross-sectionally using a questionnaire administered to women at 12 months (after the implementation of the TRI-MOM strategy) ]Proportion of women screened for HIV, Syphilis and HBV during pregnancy
- Knowledge of the targeted infections before the strategy implementation [ Time Frame: Assessed cross-sectionally using a questionnaire administered to women at baseline (before the implementation of the TRI-MOM strategy) ]Proportion of women with a good level of knowledge (defined by a score) of the targeted infections (HIV, syphilis, and HBV) and of PMTCT
- Knowledge of the targeted infections after the strategy implementation [ Time Frame: Assessed cross-sectionally using a questionnaire administered to women at 12 months (after the implementation of the TRI-MOM strategy) ]Proportion of women with a good level of knowledge (defined by a score) of the targeted infections (HIV, syphilis, and HBV) and of PMTCT
- Acceptability of the implemented strategy and PMTCT and preferences : screening refusal before the strategy implementation [ Time Frame: Assessed cross-sectionally using a questionnaire administered to women at baseline (before the implementation of the TRI-MOM strategy) ]Proportion of pregnant women who refuse the screening for any of the 3 targeted infections
- Acceptability of the implemented strategy and PMTCT and preferences : screening refusal after the strategy implementation [ Time Frame: Assessed cross-sectionally using a questionnaire administered to women at 12 months (after the implementation of the TRI-MOM strategy) ]Proportion of pregnant women who refuse the screening for any of the 3 targeted infections
- Acceptability of the implemented strategy and PMTCT and preferences : treatment refusal before the strategy implementation [ Time Frame: Assessed cross-sectionally using a questionnaire administered to women at baseline (before the implementation of the TRI-MOM strategy) ]Proportion of positive pregnant women refusing treatment
- Acceptability of the implemented strategy and PMTCT and preferences : treatment refusal after the strategy implementation [ Time Frame: Assessed cross-sectionally using a questionnaire administered to women at 12 months (after the implementation of the TRI-MOM strategy) ]Proportion of positive pregnant women refusing treatment
- Sensitivity of the hepatitis B core-related antigen rapid diagnostic test (HBcrAg-RDT) (PROTECT-B ancillary study) [ Time Frame: Data collected at cohort inclusion ]Percentage of HBsAg-positive women with a high viral load (≥200,000 IU/mL) who are positive for HBcrAg-RDT
- Specificity of the HBcrAg-RDT (PROTECT-B ancillary study) [ Time Frame: Data collected at cohort inclusion ]Percentage of HBsAg-positive women with a low viral load <200,000 IU/mL who are negative for HBcrAg-RDT
- Positive predictive value of the HBcrAg-RDT (PROTECT-B ancillary study) [ Time Frame: Data collected at cohort inclusion ]Proportion of subjects with a positive HBcrAg test result who truly have a high viral load (≥200,000 IU/mL)
- Negative predictive value of the HBcrAg-RDT (PROTECT-B ancillary study) [ Time Frame: Data collected at cohort inclusion ]Proportion of subjects with a negative HBcrAg test result who truly do not have a high viral load (≥200,000 IU/mL)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Women attending a postnatal visit in one of the selected maternities (no maternal age limit)
Exclusion Criteria:
- Refusal to participate in the study
- Unable to provide consent
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05951751
Contact: Lauren Perieres, PhD | +33 4.91.32.46.00 | lauren.perieres@inserm.fr |
Principal Investigator: | Sylvie Boyer, PhD | UMR 1252 SESSTIM |
Responsible Party: | Institut de Recherche pour le Developpement |
ClinicalTrials.gov Identifier: | NCT05951751 |
First Posted: | July 19, 2023 Key Record Dates |
Last Update Posted: | July 19, 2023 |
Last Verified: | July 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | To be completed |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
maternal health child health HIV Hepatitis B |
Syphilis prevention and control pregnancy |
Syphilis Communicable Diseases Infections Treponemal Infections Spirochaetales Infections Gram-Negative Bacterial Infections |
Bacterial Infections Bacterial Infections and Mycoses Sexually Transmitted Diseases, Bacterial Sexually Transmitted Diseases Genital Diseases Urogenital Diseases |